|
Nov 8
|
Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma
|
|
Nov 8
|
US STOCKS-S&P 500, Nasdaq barely extend win streaks as investors eye yields, Fed comments
|
|
Nov 8
|
Eli Lilly Wins FDA Nod for Obesity Drug That Rivals Wegovy, Ozempic
|
|
Nov 8
|
Eli Lilly’s Mounjaro Approved for Weight Loss in the U.S.
|
|
Nov 8
|
Here's How Lilly Plans To Unseat Novo As The Weight-Loss Drugs Kingpin
|
|
Nov 8
|
US STOCKS-Wall St ends flat as investors eye yields, Fed comments
|
|
Nov 8
|
Wegovy rival Zepbound wins approval amid weight-loss jab gold rush
|
|
Nov 8
|
UPDATE 1-UK's MHRA authorises Lilly's Mounjaro for weight loss
|
|
Nov 8
|
Novo Nordisk to discontinue Levemir insulin in U.S. market
|
|
Nov 8
|
FDA approves new version of diabetes drug Mounjaro for weight loss
|
|
Nov 8
|
UPDATE 5-Lilly weight-loss drug Zepbound gets US, UK approval to rival Wegovy
|
|
Nov 8
|
FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems
|
|
Nov 8
|
Pharma ETFs in Focus Post Q3 Earnings
|
|
Nov 8
|
Data on Pfizer’s New Weight Loss Pill Is Coming. Why it’s Crucial for the Stock.
|
|
Oct 3
|
Why Eli Lilly Stock Was Looking Sickly Today
|
|
Oct 3
|
Cruise lines, spinoff slumps, Eli Lilly-Point deal: Trending Stocks
|
|
Oct 3
|
Why Eli Lilly's $1.4 Billion Takeover Is A Boon For More Than Just Point Biopharma
|
|
Oct 3
|
Why Shares of Point Biopharma Global Are Soaring Tuesday
|
|
Oct 3
|
Eli Lilly: Point acquisition gives battered biotech sector a boost
|
|
Oct 3
|
Eli Lilly to buy cancer specialist Point for $1.4bn
|